Cellebrite DI (NASDAQ:CLBT) CMO David Nicholas Gee Sells 2,198 Shares

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 2,198 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.24, for a total transaction of $24,705.52. Following the completion of the transaction, the chief marketing officer directly owned 139,604 shares of the company’s stock, valued at $1,569,148.96. This represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

David Nicholas Gee also recently made the following trade(s):

• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total value of $3,696.10.

Cellebrite DI Stock Up 4.0%

Shares of Cellebrite DI stock opened at $11.49 on Tuesday. The stock has a market cap of $2.87 billion, a PE ratio of 52.23, a price-to-earnings-growth ratio of 1.53 and a beta of 1.18. The business has a fifty day simple moving average of $14.24 and a 200-day simple moving average of $13.83. Cellebrite DI Ltd. has a 12 month low of $9.58 and a 12 month high of $19.98.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Voss Capital LP boosted its stake in shares of Cellebrite DI by 18.9% during the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock worth $145,142,000 after acquiring an additional 1,277,300 shares in the last quarter. Pertento Partners LLP lifted its holdings in Cellebrite DI by 28.2% in the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock worth $107,447,000 after purchasing an additional 1,311,109 shares during the last quarter. Invesco Ltd. lifted its holdings in Cellebrite DI by 0.8% in the 4th quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock worth $101,026,000 after purchasing an additional 43,041 shares during the last quarter. Granahan Investment Management LLC boosted its position in Cellebrite DI by 16.3% during the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares during the period. Finally, Wellington Management Group LLP boosted its position in Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after purchasing an additional 1,475,579 shares during the period. Institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. Lake Street Capital decreased their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. DA Davidson dropped their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Weiss Ratings lowered Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.